Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRACTIB: Atezolizumab + Paclitaxel + Bevacizumab in TNBC
NCT04408118Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by MEDSIR. Started Oct 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04408118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408118.